Picture 1 of 1

Rethinking Medications : Truth, Power, and the Drugs You Take by Jerry Avorn (2025, Hardcover)

grandeagleretail (947734)

98.2% positive feedback

Price:

$28.85

Free shipping

Estimated delivery Sat, Aug 30 - Mon, Sep 8

Returns:

30 days returns. Buyer pays for return shipping. If you use an eBay shipping label, it will be deducted from your refund amount.

Condition:

Brand New

Author Jerry Avorn. --Provided by publisher. Format Hardcover.

About this product

Product Identifiers

PublisherSimon & Schuster

ISBN-101668052849

ISBN-139781668052846

eBay Product ID (ePID)3068276684

Product Key Features

Book TitleRethinking Medications : Truth, Power, and the Drugs You Take

Number of Pages512 Pages

LanguageEnglish

Publication Year2025

TopicPublic Health, Economics / General, Disease & Health Issues

GenreSocial Science, Business & Economics, Medical

AuthorJerry Avorn

FormatHardcover

Dimensions

Item Height1.1 in

Item Weight23 Oz

Item Length9 in

Item Width6 in

Additional Product Features

Intended AudienceTrade

LCCN2025-398472

Reviews"With admirable clarity and vivid examples, noted medical researcher Jerry Avorn takes a bracing multidisciplinary approach to raising and deftly answering every question you have--as well as many that may not have occurred to you--about the vital role of prescription drugs in all our lives." --Howard Gardner, author of Frames of Mind: The Theory of Multiple Intelligences and Hobbs Professor of Cognition, Harvard University, "Jerry Avorn is a leading academic force in assessing safety and efficacy of prescription drugs, in many ways serving as the conscience for the pharma industry. In Rethinking Medications , he provides a systematic and up-to-date interrogation that will be useful for patients." --Eric Topol, MD, Executive Vice President, Scripps Research Institute, and author of Deep Medicine and The Patient Will See You Now, " Rethinking Medications offers a rare combination of deep knowledge, common sense, and an engaging style; Avorn's account of pharma's achievements and scandals is simultaneously illuminating and infuriating. Americans have been paying too much for drugs and too little attention to the ways we could improve drug policy. This book is a guide to how we could be a healthier nation at a more affordable cost." --Paul Starr, Pulitzer Prize-winning author of The Social Transformation of American Medicine, "A damning survey of the drug development system's many failures, this enlightens even as it infuriates." -- Publishers Weekly

SynopsisA leading medical expert explains why too many of the medications Americans take are poorly evaluated, overpriced, or pose unwarranted risks--and what we can do to fix that. Groundbreaking research has given us many remarkable new medicines, but America's drug evaluation process, once the envy of the world, is being seriously compromised. Under pressure from drugmakers, the FDA has been lowering its approval standards and has let poorly effective or risky products enter the market--while our prescription prices, the highest in the world, put crucial treatments beyond the reach of many. In Rethinking Medications , Dr. Jerry Avorn explains how we got here and what we can do to ensure that our medicines are dependably effective, safe, and affordable. Part of the problem is the power of pharma's biggest-in-Washington lobbying clout, which influences members of Congress from both parties. That leverage is extended by the FDA's growing dependence on fees the industry pays to get its drugs approved. The increasingly revenue-driven US healthcare system shapes the way doctors prescribe medications--sometimes to the detriment of their clinical decisions. Based on his decades of practice and research at Harvard Medical School and his role at the very center of many of these controversies, Dr. Avorn presents compelling clinical illustrations of these issues across the medical spectrum: from cancer drugs to opioids, from treatments for rare diseases to psychedelics. Throughout, he offers practical steps that consumers, policymakers, and practitioners can take to address these problems--at a moment when our assumptions about scientific evidence, regulation, pricing, and the role of government are being contested as never before.

LC Classification NumberHD9666.5.A96 2025